SrasV1, PascalFrancis, Curation, bibRecord, 000483

A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

Identifieur interne : 000483 ( PascalFrancis/Curation ); précédent : 000482; suivant : 000484

A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

Auteurs : ZHIMIN ZHOU [États-Unis] ; Penny Post [États-Unis] ; Rick Chubet [États-Unis] ; Katherine Holtz [États-Unis] ; Clifton Mcpherson [États-Unis] ; Martin Petric [Canada] ; Manon Cox [États-Unis]

Source :

Vaccine [ 0264-410X ] ; 2006.

RBID : Pascal:06-0218627

Descripteurs français

Pascal (Inist)
- Baculoviridae, Virus syndrome respiratoire aigu sévère, Souris, Glycoprotéine, Vaccin, Anticorps neutralisant, Protéine recombinante, Neutralisation, Adjuvant immunologique, Syndrome respiratoire aigu sévère.
Wicri :
- topic : Vaccin.

English descriptors

KwdEn :
- Baculoviridae, Glycoprotein, Immunological adjuvant, Mouse, Neutralization, Neutralizing antibody, Recombinant protein, Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Vaccine.

Abstract

A recombinant SARS-CoV spike (S) glycoprotein vaccine produced in insect cells in a pre-clinical development stage is described. A truncated version of S glycoprotein, containing only the ecto-domain, as well as a His-tagged full-length version were cloned and expressed in a serum-free insect cell line, ExpresSF+®. The proteins, purified to apparent homogeneity by liquid column chromatography, were formulated without adjuvant at 3, 9, 27, and 50 μg per dose in phosphate saline and used to immunize mice. Both antigens in each formulation elicited a strong immune response after two or three vaccinations with the antigen. Neutralizing antibody titers correlated closely with standard ELISA reactivity against the S glycoprotein. The truncated S protein was also formulated with an adjuvant, aluminum hydroxide, at 1 μg per dose (±adjuvant), and 5 μg per dose (±adjuvant). Significantly enhanced immune responses, manifested by higher titers of serum ELISA and viral neutralizing antibodies, were achieved in adjuvanted groups with fewer doses and lower concentration of S glycoprotein. These findings indicate that the ecto-domain of SARS-CoV S glycoprotein vaccine, with or without adjuvant, is immunogenic and induces high titers of virus neutralizing antibodies to levels similar to those achieved with the full S glycoprotein vaccine.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 24`
A06				`@2 17`
A08	`01`	`1`	`ENG`	`@1 A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice`
A11	`01`	`1`		`@1 ZHIMIN ZHOU`
A11	`02`	`1`		`@1 POST (Penny)`
A11	`03`	`1`		`@1 CHUBET (Rick)`
A11	`04`	`1`		`@1 HOLTZ (Katherine)`
A11	`05`	`1`		`@1 MCPHERSON (Clifton)`
A11	`06`	`1`		`@1 PETRIC (Martin)`
A11	`07`	`1`		`@1 COX (Manon)`
A14	`01`			`@1 Protein Sciences Corporation, 1000 Research Parkway @2 Meriden, CT 06540 @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 7 aut.`
A14	`02`			`@1 BC Centre for Disease Control, 655W 12th Ave @2 Vancouver, BC, V5Z 4R4 @3 CAN @Z 6 aut.`
A20				`@1 3624-3631`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000153274560280`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 36 ref.`
A47	`01`	`1`		`@0 06-0218627`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 A recombinant SARS-CoV spike (S) glycoprotein vaccine produced in insect cells in a pre-clinical development stage is described. A truncated version of S glycoprotein, containing only the ecto-domain, as well as a His-tagged full-length version were cloned and expressed in a serum-free insect cell line, ExpresSF+®. The proteins, purified to apparent homogeneity by liquid column chromatography, were formulated without adjuvant at 3, 9, 27, and 50 μg per dose in phosphate saline and used to immunize mice. Both antigens in each formulation elicited a strong immune response after two or three vaccinations with the antigen. Neutralizing antibody titers correlated closely with standard ELISA reactivity against the S glycoprotein. The truncated S protein was also formulated with an adjuvant, aluminum hydroxide, at 1 μg per dose (±adjuvant), and 5 μg per dose (±adjuvant). Significantly enhanced immune responses, manifested by higher titers of serum ELISA and viral neutralizing antibodies, were achieved in adjuvanted groups with fewer doses and lower concentration of S glycoprotein. These findings indicate that the ecto-domain of SARS-CoV S glycoprotein vaccine, with or without adjuvant, is immunogenic and induces high titers of virus neutralizing antibodies to levels similar to those achieved with the full S glycoprotein vaccine.
C02	`01`	`X`		`@0 002A05F04`
C02	`02`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Baculoviridae @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Baculoviridae @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Baculoviridae @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Souris @5 03`
C03	`03`	`X`	`ENG`	`@0 Mouse @5 03`
C03	`03`	`X`	`SPA`	`@0 Ratón @5 03`
C03	`04`	`X`	`FRE`	`@0 Glycoprotéine @5 05`
C03	`04`	`X`	`ENG`	`@0 Glycoprotein @5 05`
C03	`04`	`X`	`SPA`	`@0 Glicoproteína @5 05`
C03	`05`	`X`	`FRE`	`@0 Vaccin @5 06`
C03	`05`	`X`	`ENG`	`@0 Vaccine @5 06`
C03	`05`	`X`	`SPA`	`@0 Vacuna @5 06`
C03	`06`	`X`	`FRE`	`@0 Anticorps neutralisant @5 07`
C03	`06`	`X`	`ENG`	`@0 Neutralizing antibody @5 07`
C03	`06`	`X`	`SPA`	`@0 anticuerpo neutralizante @5 07`
C03	`07`	`X`	`FRE`	`@0 Protéine recombinante @5 08`
C03	`07`	`X`	`ENG`	`@0 Recombinant protein @5 08`
C03	`07`	`X`	`SPA`	`@0 Proteína recombinante @5 08`
C03	`08`	`X`	`FRE`	`@0 Neutralisation @5 09`
C03	`08`	`X`	`ENG`	`@0 Neutralization @5 09`
C03	`08`	`X`	`SPA`	`@0 Neutralización @5 09`
C03	`09`	`X`	`FRE`	`@0 Adjuvant immunologique @5 10`
C03	`09`	`X`	`ENG`	`@0 Immunological adjuvant @5 10`
C03	`09`	`X`	`SPA`	`@0 Coadyuvante inmunológico @5 10`
C03	`10`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 14`
C03	`10`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 14`
C03	`10`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 14`
C07	`01`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`03`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`04`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`05`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`05`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`05`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`06`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`06`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`06`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`07`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`07`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`07`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`08`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 13`
C07	`08`	`X`	`ENG`	`@0 Respiratory disease @5 13`
C07	`08`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 13`
C07	`09`	`X`	`FRE`	`@0 Virose`
C07	`09`	`X`	`ENG`	`@0 Viral disease`
C07	`09`	`X`	`SPA`	`@0 Virosis`
C07	`10`	`X`	`FRE`	`@0 Infection`
C07	`10`	`X`	`ENG`	`@0 Infection`
C07	`10`	`X`	`SPA`	`@0 Infección`
C07	`11`	`X`	`FRE`	`@0 Poumon pathologie @5 16`
C07	`11`	`X`	`ENG`	`@0 Lung disease @5 16`
C07	`11`	`X`	`SPA`	`@0 Pulmón patología @5 16`
N21				`@1 135`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000507

Links to Exploration step

Pascal:06-0218627

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice</title>
<author><name sortKey="Zhimin Zhou" sort="Zhimin Zhou" uniqKey="Zhimin Zhou" last="Zhimin Zhou">ZHIMIN ZHOU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Post, Penny" sort="Post, Penny" uniqKey="Post P" first="Penny" last="Post">Penny Post</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chubet, Rick" sort="Chubet, Rick" uniqKey="Chubet R" first="Rick" last="Chubet">Rick Chubet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Holtz, Katherine" sort="Holtz, Katherine" uniqKey="Holtz K" first="Katherine" last="Holtz">Katherine Holtz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mcpherson, Clifton" sort="Mcpherson, Clifton" uniqKey="Mcpherson C" first="Clifton" last="Mcpherson">Clifton Mcpherson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>BC Centre for Disease Control, 655W 12th Ave</s1>
<s2>Vancouver, BC, V5Z 4R4</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Cox, Manon" sort="Cox, Manon" uniqKey="Cox M" first="Manon" last="Cox">Manon Cox</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0218627</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0218627 INIST</idno>
<idno type="RBID">Pascal:06-0218627</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000507</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000483</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice</title>
<author><name sortKey="Zhimin Zhou" sort="Zhimin Zhou" uniqKey="Zhimin Zhou" last="Zhimin Zhou">ZHIMIN ZHOU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Post, Penny" sort="Post, Penny" uniqKey="Post P" first="Penny" last="Post">Penny Post</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chubet, Rick" sort="Chubet, Rick" uniqKey="Chubet R" first="Rick" last="Chubet">Rick Chubet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Holtz, Katherine" sort="Holtz, Katherine" uniqKey="Holtz K" first="Katherine" last="Holtz">Katherine Holtz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mcpherson, Clifton" sort="Mcpherson, Clifton" uniqKey="Mcpherson C" first="Clifton" last="Mcpherson">Clifton Mcpherson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>BC Centre for Disease Control, 655W 12th Ave</s1>
<s2>Vancouver, BC, V5Z 4R4</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Cox, Manon" sort="Cox, Manon" uniqKey="Cox M" first="Manon" last="Cox">Manon Cox</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Baculoviridae</term>
<term>Glycoprotein</term>
<term>Immunological adjuvant</term>
<term>Mouse</term>
<term>Neutralization</term>
<term>Neutralizing antibody</term>
<term>Recombinant protein</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Baculoviridae</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Souris</term>
<term>Glycoprotéine</term>
<term>Vaccin</term>
<term>Anticorps neutralisant</term>
<term>Protéine recombinante</term>
<term>Neutralisation</term>
<term>Adjuvant immunologique</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A recombinant SARS-CoV spike (S) glycoprotein vaccine produced in insect cells in a pre-clinical development stage is described. A truncated version of S glycoprotein, containing only the ecto-domain, as well as a His-tagged full-length version were cloned and expressed in a serum-free insect cell line, ExpresSF+®. The proteins, purified to apparent homogeneity by liquid column chromatography, were formulated without adjuvant at 3, 9, 27, and 50 μg per dose in phosphate saline and used to immunize mice. Both antigens in each formulation elicited a strong immune response after two or three vaccinations with the antigen. Neutralizing antibody titers correlated closely with standard ELISA reactivity against the S glycoprotein. The truncated S protein was also formulated with an adjuvant, aluminum hydroxide, at 1 μg per dose (±adjuvant), and 5 μg per dose (±adjuvant). Significantly enhanced immune responses, manifested by higher titers of serum ELISA and viral neutralizing antibodies, were achieved in adjuvanted groups with fewer doses and lower concentration of S glycoprotein. These findings indicate that the ecto-domain of SARS-CoV S glycoprotein vaccine, with or without adjuvant, is immunogenic and induces high titers of virus neutralizing antibodies to levels similar to those achieved with the full S glycoprotein vaccine.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>17</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ZHIMIN ZHOU</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>POST (Penny)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHUBET (Rick)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HOLTZ (Katherine)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MCPHERSON (Clifton)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>PETRIC (Martin)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>COX (Manon)</s1>
</fA11>
<fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1>
<s2>Meriden, CT 06540</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>BC Centre for Disease Control, 655W 12th Ave</s1>
<s2>Vancouver, BC, V5Z 4R4</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>3624-3631</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000153274560280</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>36 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0218627</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A recombinant SARS-CoV spike (S) glycoprotein vaccine produced in insect cells in a pre-clinical development stage is described. A truncated version of S glycoprotein, containing only the ecto-domain, as well as a His-tagged full-length version were cloned and expressed in a serum-free insect cell line, ExpresSF+®. The proteins, purified to apparent homogeneity by liquid column chromatography, were formulated without adjuvant at 3, 9, 27, and 50 μg per dose in phosphate saline and used to immunize mice. Both antigens in each formulation elicited a strong immune response after two or three vaccinations with the antigen. Neutralizing antibody titers correlated closely with standard ELISA reactivity against the S glycoprotein. The truncated S protein was also formulated with an adjuvant, aluminum hydroxide, at 1 μg per dose (±adjuvant), and 5 μg per dose (±adjuvant). Significantly enhanced immune responses, manifested by higher titers of serum ELISA and viral neutralizing antibodies, were achieved in adjuvanted groups with fewer doses and lower concentration of S glycoprotein. These findings indicate that the ecto-domain of SARS-CoV S glycoprotein vaccine, with or without adjuvant, is immunogenic and induces high titers of virus neutralizing antibodies to levels similar to those achieved with the full S glycoprotein vaccine.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Baculoviridae</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Baculoviridae</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Baculoviridae</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Souris</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Mouse</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Ratón</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Glycoprotéine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Glycoprotein</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Glicoproteína</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Anticorps neutralisant</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Neutralizing antibody</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>anticuerpo neutralizante</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Protéine recombinante</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Recombinant protein</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Proteína recombinante</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Neutralisation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Neutralization</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Neutralización</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Adjuvant immunologique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Immunological adjuvant</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Coadyuvante inmunológico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>13</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>13</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>13</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>16</s5>
</fC07>
<fN21><s1>135</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000483 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000483 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0218627
   |texte=   A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri